(0.01%) 5 214.57 points
(0.20%) 39 467 points
(-0.19%) 16 314 points
(-1.16%) $78.34
(-1.43%) $2.27
(1.50%) $2 375.50
(0.49%) $28.50
(1.53%) $1 006.00
(0.09%) $0.928
(-0.21%) $10.84
(-0.05%) $0.798
(0.15%) $92.68
@ $3.41
Issued: 12 Feb 2024 @ 14:19
Return: 20.23%
Previous signal: Feb 8 - 12:41
Previous signal:
Return: -5.28 %
Live Chart Being Loaded With Signals
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors...
Stats | |
---|---|
Today's Volume | 8 831.00 |
Average Volume | 38 032.00 |
Market Cap | 56.21M |
EPS | $0 ( 2024-04-01 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.97 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Wesolowski John M | Buy | 25 000 | Stock Option (right to buy Common Stock) |
2024-03-06 | Leahy Emer | Buy | 50 000 | Stock Option (right to buy Common Stock) |
2024-03-06 | Goldberg Mark A | Buy | 50 000 | Stock Option (right to buy Common Stock) |
2024-03-06 | Donovan Daniel | Buy | 50 000 | Stock Option (right to buy Common Stock) |
2024-03-06 | Bender Lewis H | Buy | 464 805 | Stock Option (right to buy Common Stock) |
INSIDER POWER |
---|
57.42 |
Last 23 transactions |
Buy: 803 379 | Sell: 331 500 |
Intensity Therapeutics, Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Intensity Therapeutics, Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-147 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-147 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-179 037 (0.00 %) |
EPS: | $-0.570 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.439 |
Financial Reports:
No articles found.
Intensity Therapeutics,
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators